10-Year Free Cash Flow Projections(showing years 1, 3, 5, 7, 10)
| Year | Year 1 | Year 3 | Year 5 | Year 7 | Year 10 |
|---|
| Revenue | $14.7B | $16.2B | $15.2B | $13.0B | $13.0B |
| EBIT | $1.8B | $2.0B | $1.8B | $1.9B | $2.3B |
| Tax | $368M | $406M | $382M | $402M | $468M |
| NOPAT | $1.4B | $1.5B | $1.5B | $1.5B | $1.8B |
| + Depreciation | $635M | $700M | $658M | $561M | $560M |
| - Capex | $488M | $538M | $506M | $432M | $431M |
| - Δ NWC | $70M | $77M | -$205M | -$82M | $37M |
| Free Cash Flow | $1.5B | $1.6B | $1.8B | $1.7B | $1.9B |
| Discount Factor | 0.931 | 0.807 | 0.699 | 0.606 | 0.489 |
| Present Value | $1.4B | $1.3B | $1.3B | $1.1B | $919M |
FCF Formula: Free Cash Flow = NOPAT + Depreciation - Capex - Change in Net Working Capital
Sensitivity AnalysisPrice per Share
| WACC ↓ / Growth → | 2.00% | 2.50% | 3.00% | 3.50% | 4.00% |
|---|
| 5.42% | $512.61 | $547.78 | $597.48 | $653.67 | $624.71 |
| 6.42% | $424.80 | $443.42 | $467.49 | $499.79 | $545.44 |
| 7.42% | $362.45 | $373.57 | $387.21 | $404.32 | $426.44 |
| 8.42% | $314.52 | $321.69 | $330.20 | $340.43 | $352.97 |
| 9.42% | $275.81 | $280.71 | $286.36 | $292.97 | $300.80 |
How to read: This table shows how the valuation changes with different WACC (discount rate) and terminal growth rate assumptions. Green = undervalued, Red = overvalued.
Key Assumptions & Drivers✓ Using Analyst Consensus Estimates• Healthcare Sector
Growth Assumptions (Select Years)
Year 1 Revenue Growth5.19%
Year 3 Revenue Growth5.15%
Year 5 Revenue Growth-12.20%
Year 7 Revenue Growth-6.12%
Year 10 Revenue Growth3.00%
Terminal Growth Rate3.00%
Margin & Efficiency
Current EBIT Margin12.08%
Terminal EBIT Margin20.00%
Tax Rate20.75%
Historical Capex / Rev3.33%
NWC / Revenue9.70%
Key Drivers: Revenue growth, operating margin expansion, capex efficiency, and working capital management are the primary drivers of cash flow generation. Terminal value assumptions significantly impact final valuation.
Institutional-Grade Methodology
Actual Company Data: Revenue, EBIT, Capex, NWC, Tax Rate, Interest Expense, Beta
Market Assumptions: Risk-free: 4.5% (10Y), MRP: 4.5% (Damodaran 2026), Exit: 24x EV/EBITDA (Healthcare sector)
This DCF model is for informational purposes only. Projections are based on assumptions that may not materialize. Past performance does not guarantee future results. Consult a financial advisor before making investment decisions.